NCT04566679 (BUZIR) is a NA clinical trial of Dibuzin in Irritable Bowel Syndrome (IBS), sponsored by University of Bari.

Who is sponsoring NCT04566679?

NCT04566679 is sponsored by University of Bari.

What drugs are being tested in NCT04566679?

Interventions in NCT04566679: Dibuzin, placebo.

What condition does NCT04566679 study?

NCT04566679 studies Irritable Bowel Syndrome (IBS), Children, Only.

Is NCT04566679 still recruiting?

NCT04566679 is currently status unknown. Last updated 23 April 2021.

Last reviewed 2021-04-23 · How we verify

NCT04566679: BUZIR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Butyrate in Children With IBS: Double Blind Placebo Controlled Randomized Clinical Trial

Status unknown NA Last updated 23 April 2021

What this trial tests

NA trial testing Dibuzin in Irritable Bowel Syndrome (IBS) in 50 participants. Status unknown.

Timeline

21 April 2021

Primary endpoint
1 January 2023

1 January 2023

Quick facts

Lead sponsor	University of Bari
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	21 April 2021
Primary completion	1 January 2023
Estimated completion	1 January 2023
Sites	2 locations across Italy

Drugs / interventions tested

Dibuzin
placebo

Conditions studied

Irritable Bowel Syndrome (IBS) — all drugs for Irritable Bowel Syndrome (IBS) →
Children, Only — all drugs for Children, Only →

Sponsor

University of Bari

Who can join

Adults 4 to 16, any sex, with Irritable Bowel Syndrome (IBS) or Children, Only. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We will perform a randomized, double-blind, placebo-controlled trial to establish whether calcium butyrate relieves symptoms in children with irritable bowel syndrome (IBS). The direct effects of butyrate on inflammation and GI symptoms will be studied in children with IBS. The design used to study the effects of calcium butyrate will be a double blind randomized placebo-controlled parallel design.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial.
Cristofori F, Calabrese FM, Iacobellis I, Santamaria M, et al · · 2025 · cited 1× · PMID 40635319 · DOI 10.1002/jpn3.70154

Verify or expand the search:

Other recruiting trials for Irritable Bowel Syndrome (IBS)

Currently open trials in the same condition.

NCT07481422 — Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndro · Phase 1, PHASE2 · recruiting
NCT07261826 — Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics · recruiting
NCT07000227 — Mechanism of FODMAP Restriction on FGID Patients · NA · recruiting
NCT06647043 — Evaluate the Effect of Synbiotics in Irritable Bowel Syndrome · NA · recruiting
NCT06668922 — Irritable Bowel Syndrome and Control Volunteers: Diet Challenge · NA · recruiting

Other University of Bari trials

Trials by the same sponsor.

NCT06854133 — Factors of Effectiveness in Italian Forensic Treatment · not yet recruiting
NCT07125625 — Probiotic Mixture (L. Rhamnosus GG and L. Plantarum 299V) In Pediatric Irritable Bowel Syndrome · NA · not yet recruiting
NCT07036627 — Intestinal Microbiota After PPI Treatment · not yet recruiting
NCT07050693 — Efficacy of a 2'-Fucosylactose-based Food Supplement on the Prevention of Respiratory and Gastrointestinal Infections. · NA · recruiting
NCT06719999 — PRIMA Project- Box for Heath and Tradition (B4HT) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04566679 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bari
Last refreshed: 23 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04566679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing